ZVRA

Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

Wall Street analysts forecast ZVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZVRA is 24.00 USD with a low forecast of 21.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Zevra Therapeutics Inc revenue for the last quarter amounts to 26.06M USD, increased 605.36 % YoY.

Zevra Therapeutics Inc. EPS for the last quarter amounts to -0.01 USD, decreased -98.55 % YoY.

Zevra Therapeutics Inc (ZVRA) has 59 emplpoyees as of December 15 2025.

Today ZVRA has the market capitalization of 468.96M USD.